Cadila Healthcare is currently trading at Rs. 365.05, up by 4.10 points or 1.14% from its previous closing of Rs. 360.95 on the BSE.
The scrip opened at Rs. 362.80 and has touched a high and low of Rs. 368.25 and Rs. 362.00 respectively. So far 157081 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 383.65 on 15-Jun-2020 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 368.25 and Rs. 352.20 respectively. The current market cap of the company is Rs. 37499.69 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.15% and 7.78% respectively.
Zydus Cadila has received approval from the Mexican regulatory authority COFEPRIS to conduct clinical trials with its biological therapy, Pegylated Interferon alpha-2b, ‘PegiHepTM’. This will be an open-label, randomized, comparator controlled study of Pegylated IFN alfa-2b to evaluate safety, efficacy and tolerability in patients with COVID-19. Clinical and regulatory development of Pegylated Interferon alpha-2b in COVID-19 is being executed in Mexico by Avant Santé Research Center S.A. de C.V., a leading Contract Research Organization (CRO).
The company had earlier approached the DCGI to investigate the role of Pegylated Interferon alpha-2b for COVID 19 and the clinical trials are now underway. The Company is also working with USFDA to open an Investigational New Drug (IND) application for Pegylated Interferon alpha-2b.
Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1545.25 |
Dr. Reddys Lab | 5861.00 |
Cipla | 1356.95 |
Zydus Lifesciences | 984.75 |
Lupin | 1635.00 |
View more.. |